{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:07:51Z","timestamp":1792814871965,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_184790"],"award-info":[{"award-number":["310030_184790"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["182317"],"award-info":[{"award-number":["182317"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Multiple myeloma is a plasma cell malignancy with a poor prognosis despite the recent development of new therapeutic options. Histone deacetylase 6 (HDAC6) is overexpressed in multiple myeloma cells and may be involved in the acquisition of resistance to conventional anti-proteasome treatments. In addition to displaying a deacetylase catalytic activity, HDAC6 plays an essential role in the regulation of autophagy and cell death by recognizing ubiquitinated motifs from misfolded proteins through its C-terminal ZnF-UBP binding domain. These defective proteins are sent to the aggresome to facilitate their degradation by autophagy. Here, we explore the role of the ZnF-UBP binding domain of HDAC6 in the function of multiple myeloma cells. A non-functional ZnF-UBP domain containing a 2-residue mutation in the binding site was designed, and the absence of ubiquitin binding was confirmed in a cell-free assay. Molecular docking simulations and electrostatic calculations revealed a significant decrease in the electrostatic potential of the mutated peptide, which is crucial for the stability of the complex with ubiquitin. A multiple myeloma cell line containing the non-functional ZnF-UBP domain was then engineered. Although the deacetylase activity of HDAC6 was maintained in these cells, they showed reduced cell growth, impaired aggresome formation, and a dysregulated gene expression profile that was more pronounced than cells entirely deficient in HDAC6. These results indicate that a non-functional ZnF-UBP binding domain impacts the function of multiple myeloma cells. Based on these findings, a series of quinazolinylpropanoic acid derivatives was synthesized to explore the inhibitory activity of small molecules to this domain. We propose that ZnF-UBP binding domain inhibitors should be further evaluated as potential therapeutic agents in multiple myeloma.<\/jats:p>","DOI":"10.1038\/s41420-025-02465-1","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T21:49:11Z","timestamp":1744753751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Selective molecular inhibition of the HDAC6 ZnF-UBP binding domain impairs multiple myeloma cell function"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7371-7323","authenticated-orcid":false,"given":"Rafael","family":"Rinc\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"F. Coira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Richieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8296-709X","authenticated-orcid":false,"given":"Fedaa","family":"Attana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Urwyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2650-2925","authenticated-orcid":false,"given":"Shozeb","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3862-4583","authenticated-orcid":false,"given":"Carole","family":"Bourquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1523-1907","authenticated-orcid":false,"given":"Muriel","family":"Cuendet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2465_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hon.2586","volume":"37","author":"SV Rajkumar","year":"2019","unstructured":"Rajkumar SV. Multiple myeloma: Every year a new standard? Hematol Oncol. 2019;37:62\u20135.","journal-title":"Hematol Oncol"},{"key":"2465_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327.","journal-title":"Lancet"},{"key":"2465_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327:464\u201377.","journal-title":"JAMA"},{"key":"2465_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548\u201367.","journal-title":"Am J Hematol"},{"key":"2465_CR5","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","volume":"13","author":"T Liang","year":"2023","unstructured":"Liang T, Wang F, Elhassan RM, Cheng Y, Tang X, Chen W, et al. Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharm Sin B. 2023;13:2425\u201363.","journal-title":"Acta Pharm Sin B"},{"key":"2465_CR6","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.4161\/15592294.2014.983367","volume":"9","author":"S Mithraprabhu","year":"2014","unstructured":"Mithraprabhu S, Kalff A, Chow A, Khong T, Spencer A. Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 2014;9:1511\u201320.","journal-title":"Epigenetics"},{"key":"2465_CR7","first-page":"888","volume":"4","author":"T Cheng","year":"2021","unstructured":"Cheng T, Kiser K, Grasse L, Iles L, Bartholomeusz G, Samaniego F, et al. Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat. Cancer Drug Resist. 2021;4:888\u2013902.","journal-title":"Cancer Drug Resist"},{"key":"2465_CR8","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood-2015-09-665018","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016;127:713\u201321.","journal-title":"Blood"},{"key":"2465_CR9","first-page":"16742","volume":"87","author":"U.S. Food and Drug Administration.","year":"2022","unstructured":"U.S. Food and Drug Administration. Withdrawal of approval of new drug application for Farydak (panobinostat) capsules, 10 milligrams, 15 milligrams, and 20 milligrams. Fed Reg. 2022;87:16742\u20133.","journal-title":"Fed Reg"},{"key":"2465_CR10","doi-asserted-by":"publisher","first-page":"29168","DOI":"10.1074\/jbc.M112.371120","volume":"287","author":"Y Liu","year":"2012","unstructured":"Liu Y, Peng L, Seto E, Huang S, Qiu Y. Modulation of histone deacetylase 6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation. J Biol Chem. 2012;287:29168\u201374.","journal-title":"J Biol Chem"},{"key":"2465_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1021\/acs.jmedchem.9b00924","volume":"63","author":"M Brindisi","year":"2020","unstructured":"Brindisi M, Saraswati AP, Brogi S, Gemma S, Butini S, Campiani G. Old but gold: Tracking the new guise of histone deacetylase 6 (HDAC6) enzyme as a biomarker and therapeutic target in rare diseases. J Med Chem. 2020;63:23\u201339.","journal-title":"J Med Chem"},{"key":"2465_CR12","volume":"2011","author":"GI Aldana-Masangkay","year":"2011","unstructured":"Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol. 2011;2011:875824.","journal-title":"J Biomed Biotechnol"},{"key":"2465_CR13","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1074\/jbc.M111.273730","volume":"287","author":"H Ouyang","year":"2012","unstructured":"Ouyang H, Ali YO, Ravichandran M, Dong A, Qiu W, MacKenzie F, et al. Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini. J Biol Chem. 2012;287:2317\u201327.","journal-title":"J Biol Chem"},{"key":"2465_CR14","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1101\/gad.436407","volume":"21","author":"C Boyault","year":"2007","unstructured":"Boyault C, Zhang Y, Fritah S, Caron C, Gilquin B, Kwon SH, et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev. 2007;21:2172\u201381.","journal-title":"Genes Dev"},{"key":"2465_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fonc.2019.00249","volume":"9","author":"FI Huang","year":"2019","unstructured":"Huang FI, Wu YW, Sung TY, Liou JP, Lin MH, Pan SL, et al. MPT0G413, a novel HDAC6-selective inhibitor, and bortezomib synergistically exert anti-tumor activity in multiple myeloma cells. Front Oncol. 2019;9:249.","journal-title":"Front Oncol"},{"key":"2465_CR16","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3390\/ijms22031341","volume":"22","author":"SW Lee","year":"2021","unstructured":"Lee SW, Yeon SK, Kim GW, Lee DH, Jeon YH, Yoo J. HDAC6-selective inhibitor overcomes bortezomib resistance in multiple myeloma. Int J Mol Sci.2021;22:1341.","journal-title":"Int J Mol Sci."},{"key":"2465_CR17","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","volume":"17","author":"AJ Yee","year":"2016","unstructured":"Yee AJ, Bensinger WI, Supko JG, Voorhees PM, Berdeja JG, Richardson PG, et al. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Lancet Oncol. 2016;17:1569\u201378.","journal-title":"Lancet Oncol"},{"key":"2465_CR18","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-16-2526","volume":"23","author":"DT Vogl","year":"2017","unstructured":"Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R, et al. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin Cancer Res. 2017;23:3307\u201315.","journal-title":"Clin Cancer Res"},{"key":"2465_CR19","doi-asserted-by":"publisher","first-page":"13459","DOI":"10.1073\/pnas.1718823114","volume":"114","author":"NJ Porter","year":"2017","unstructured":"Porter NJ, Mahendran A, Breslow R, Christianson DW. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors. Proc Natl Acad Sci USA. 2017;114:13459\u201364.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2465_CR20","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1021\/acs.jmedchem.8b00258","volume":"61","author":"R Ferreira de Freitas","year":"2018","unstructured":"Ferreira de Freitas R, Harding RJ, Franzoni I, Ravichandran M, Mann MK, Ouyang H, et al. Identification and structure-activity relationship of HDAC6 zinc-finger ubiquitin binding domain inhibitors. J Med Chem. 2018;61:4517\u201327.","journal-title":"J Med Chem"},{"key":"2465_CR21","doi-asserted-by":"publisher","first-page":"10273","DOI":"10.1021\/acs.jmedchem.3c00314","volume":"66","author":"RJ Harding","year":"2023","unstructured":"Harding RJ, Franzoni I, Mann MK, Szewczyk MM, Mirabi B, Ferreira de Freitas R, et al. Discovery and characterization of a chemical probe targeting the zinc-finger ubiquitin-binding domain of HDAC6. J Med Chem. 2023;66:10273\u201388.","journal-title":"J Med Chem"},{"key":"2465_CR22","doi-asserted-by":"publisher","unstructured":"Dong A, Ravichandran, M., Loppnau, P., Li, Y., MacKenzie, F., Kozieradzki, et al. Structural Genomics Consortium (SGC). Crystal structure of human HDAC6 zinc finger domain and ubiquitin C-terminal peptide RLRGG https:\/\/doi.org\/10.2210\/pdb3GV4\/pdb (2009).","DOI":"10.2210\/pdb3GV4\/pdb"},{"key":"2465_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/417455a","volume":"417","author":"C Hubbert","year":"2002","unstructured":"Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417:455\u20138.","journal-title":"Nature"},{"key":"2465_CR24","doi-asserted-by":"publisher","first-page":"20646","DOI":"10.1039\/D3RA03702A","volume":"13","author":"A Richieu","year":"2023","unstructured":"Richieu A, Bertrand P. Convergent micro-wave assisted synthesis of quinazolinone and its precursor using the bio-sourced solvent pinane. RSC Adv. 2023;13:20646\u201350.","journal-title":"RSC Adv"},{"key":"2465_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46237-1","volume":"9","author":"S Anisimov","year":"2019","unstructured":"Anisimov S, Takahashi M, Kakihana T, Katsuragi Y, Kitaura H, Zhang L, et al. G3BP1 inhibits ubiquitinated protein aggregations induced by p62 and USP10. Sci Rep. 2019;9:12896.","journal-title":"Sci Rep"},{"key":"2465_CR26","doi-asserted-by":"publisher","first-page":"14997","DOI":"10.3390\/ijms150914997","volume":"15","author":"L Zhou","year":"2014","unstructured":"Zhou L, Wang H, Chen D, Gao F, Ying Z, Wang G. p62\/sequestosome 1 regulates aggresome formation of pathogenic ataxin-3 with expanded polyglutamine. Int J Mol Sci. 2014;15:14997\u20135010.","journal-title":"Int J Mol Sci"},{"key":"2465_CR27","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.celrep.2015.01.017","volume":"10","author":"S Chattopadhyay","year":"2015","unstructured":"Chattopadhyay S, Stewart AL, Mukherjee S, Huang C, Hartwell KA, Miller PG, et al. Niche-based screening in multiple myeloma identifies a kinesin-5 inhibitor with improved selectivity over hematopoietic progenitors. Cell Rep. 2015;10:755\u201370.","journal-title":"Cell Rep."},{"key":"2465_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1365-2141.2010.08248.x","volume":"150","author":"X Wang","year":"2010","unstructured":"Wang X, Sinn AL, Pollok K, Sandusky G, Zhang S, Chen L, et al. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol. 2010;150:313\u201325.","journal-title":"Br J Haematol"},{"key":"2465_CR29","doi-asserted-by":"publisher","DOI":"10.2217\/ijh-2021-0017","volume":"11","author":"M Bou Zerdan","year":"2022","unstructured":"Bou Zerdan M, Nasr L, Kassab J, Saba L, Ghossein M, Yaghi M, et al. Adhesion molecules in multiple myeloma oncogenesis and targeted therapy. Int J Hematol Oncol. 2022;11:IJH39.","journal-title":"Int J Hematol Oncol"},{"key":"2465_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","volume":"9","author":"L Sanchez","year":"2016","unstructured":"Sanchez L, Wang Y, Siegel DS, Wang ML. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016;9:51.","journal-title":"J Hematol Oncol"},{"key":"2465_CR31","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1365-2141.2011.08864.x","volume":"155","author":"K Podar","year":"2011","unstructured":"Podar K, Zimmerhackl A, Fulciniti M, Tonon G, Hainz U, Tai YT, et al. The selective adhesion molecule inhibitor natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol. 2011;155:438\u201348.","journal-title":"Br J Haematol"},{"key":"2465_CR32","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.3389\/fimmu.2020.01776","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wang K, Fu J. HDAC6 mediates poly (I:C)-induced TBK1 and Akt phosphorylation in macrophages. Front Immunol. 2020;11:1776.","journal-title":"Front Immunol"},{"key":"2465_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.molimm.2014.02.019","volume":"60","author":"F Cheng","year":"2014","unstructured":"Cheng F, Lienlaf M, Perez-Villarroel P, Wang HW, Lee C, Woan K, et al. Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Mol Immunol. 2014;60:44\u201353.","journal-title":"Mol Immunol"},{"key":"2465_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109166","volume":"117","author":"WB Zhang","year":"2019","unstructured":"Zhang WB, Yang F, Wang Y, Jiao FZ, Zhang HY, Wang LW, et al. Inhibition of HDAC6 attenuates LPS-induced inflammation in macrophages by regulating oxidative stress and suppressing the TLR4-MAPK\/NF-kappaB pathways. Biomed Pharmacother. 2019;117:109166.","journal-title":"Biomed Pharmacother"},{"key":"2465_CR35","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3389\/fendo.2018.00788","volume":"9","author":"D Harmer","year":"2018","unstructured":"Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Front Endocrinol (Lausanne). 2018;9:788.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2465_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-018-0654-9","volume":"11","author":"T Li","year":"2018","unstructured":"Li T, Zhang C, Hassan S, Liu X, Song F, Chen K, et al. Histone deacetylase 6 in cancer. J Hematol Oncol 2018;11:111.","journal-title":"J Hematol Oncol"},{"key":"2465_CR37","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput 2015;11:3696\u2013713.","journal-title":"J Chem Theory Comput"},{"key":"2465_CR38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1021\/acs.jctc.7b00773","volume":"14","author":"Z Yu","year":"2018","unstructured":"Yu Z, Li P, Merz KM Jr. Extended zinc AMBER force field (EZAFF). J Chem Theory Comput 2018;14:242\u201354.","journal-title":"J Chem Theory Comput"},{"key":"2465_CR39","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1063\/1.445869","volume":"79","author":"WL Jorgensen","year":"1983","unstructured":"Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983;79:926\u201335.","journal-title":"J Chem Phys"},{"key":"2465_CR40","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1021\/ct9000685","volume":"5","author":"MJ Harvey","year":"2009","unstructured":"Harvey MJ, Giupponi G, Fabritiis GD. ACEMD: Accelerating biomolecular dynamics in the microsecond time scale. J Chem Theory Comput 2009;5:1632\u20139.","journal-title":"J Chem Theory Comput"},{"key":"2465_CR41","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/jcc.21787","volume":"32","author":"N Michaud-Agrawal","year":"2011","unstructured":"Michaud-Agrawal N, Denning EJ, Woolf TB, Beckstein O. MDAnalysis: a toolkit for the analysis of molecular dynamics simulations. J Comput Chem. 2011;32:2319\u201327.","journal-title":"J Comput Chem"},{"key":"2465_CR42","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/pro.3280","volume":"27","author":"E Jurrus","year":"2018","unstructured":"Jurrus E, Engel D, Star K, Monson K, Brandi J, Felberg LE, et al. Improvements to the APBS biomolecular solvation software suite. Protein Sci. 2018;27:112\u201328.","journal-title":"Protein Sci"},{"key":"2465_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng EC, Goddard TD, Pettersen EF, Couch GS, Pearson ZJ, Morris JH, et al. UCSF ChimeraX: Tools for structure building and analysis. Protein Sci. 2023;32:e4792.","journal-title":"Protein Sci"},{"key":"2465_CR44","doi-asserted-by":"crossref","unstructured":"Simoes-Pires CA, Zwick V, Cretton S, Cuendet M. Simultaneous measurement of HDAC1 and HDAC6 activity in HeLa cells using UHPLC-MS. J Vis Exp. 2017;e55878.","DOI":"10.3791\/55878-v"},{"key":"2465_CR45","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1021\/acs.jcim.8b00545","volume":"59","author":"M Su","year":"2019","unstructured":"Su M, Yang Q, Du Y, Feng G, Liu Z, Li Y, et al. Comparative assessment of scoring functions: The CASF-2016 update. J Chem Inf Model. 2019;59:895\u2013913.","journal-title":"J Chem Inf Model"},{"key":"2465_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"2465_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139\u201340.","journal-title":"Bioinformatics"},{"key":"2465_CR48","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137.","journal-title":"OMICS"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02465-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02465-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02465-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T23:02:53Z","timestamp":1744758173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02465-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2465"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02465-1","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"29 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the methods were performed in accordance with the relevant guidelines and regulations. The in vitro experiments (recombinant proteins and cells) performed in this work did not use material that requires ethical approval, and no experiments were conducted on animals or human patients\u2019 samples.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"176"}}